Table 1.
Baseline characteristics.
| Characteristics | Telehealth care group (N=431) | Control group (N=1549) | P value | |
| Patient status | ||||
| Age (years), mean (SD) | 70.3 (14.9) | 64.2 (13.8) | <.001 | |
| Age > 80 years, n (%) | 85 (19.7) | 115 (7.4) | <.001 | |
| Female gender, n (%) | 146 (33.9) | 494 (31.9) | .45 | |
| Risk factors | ||||
| Diabetes mellitus, n (%) | 128 (29.7) | 369 (23.8) | .01 | |
| Hypertension, n (%) | 198 (45.9) | 642 (41.4) | .098 | |
| Hyperlipidemia, n (%) | 143 (33.2) | 484 (31.2) | .40 | |
| Atrial fibrillation, n (%) | 73 (16.9) | 152 (9.8) | <.001 | |
| CKDa, n (%) | 38 (8.8) | 116 (7.5) | .36 | |
| CADb, n (%) | 207 (48.0) | 907 (58.6) | <.001 | |
| CHFc, n (%) | 103 (23.9) | 166 (10.7) | <.001 | |
| Stroke, n (%) | 64 (14.8) | 128 (8.3) | <.001 | |
| PADd, n (%) | 14 (3.2) | 51 (3.3) | >.99 | |
| CHA2DS2-VASce score, mean (SD) | 2.7 (1.9) | 2.0 (1.6) | <.001 | |
| Medication | ||||
| Aspirin, n (%) | 184 (42.7%) | 788 (50.9%) | .003 | |
| Beta-blocker, n (%) | 150 (34.8%) | 321 (20.7%) | <.001 | |
| ACEI/ARBf, n (%) | 170 (39.4%) | 510 (32.3%) | .01 | |
| CCBg, n (%) | 44 (10.2%) | 390 (25.2%) | <.001 | |
| Statin, n (%) | 120 (27.8%) | 440 (28.4%) | .86 | |
| OHAh, n (%) | 78 (18.1%) | 229 (14.8%) | .098 | |
| Mean follow-up (days), mean (SD) | 701.7 (431.4) | 886.1 (530.9) | <.001 | |
aCKD: chronic kidney disease.
bCAD: coronary artery disease.
cCHF: congestive heart failure.
dPAD: peripheral artery disease.
eCHA2DS2-VASc: congestive heart failure, hypertension, age >75 years (doubled), type 2 diabetes mellitus, previous stroke, transient ischemic attack or thromboembolism (doubled), vascular disease, age of 65-75 years, and sex.
fACEI/ARB: angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker.
gCCB: calcium channel blocker.
hOHA: oral hypoglycemic agent.